{
    "relation": [
        [
            "",
            "7-day Lamivudine/Zidovudine (3TC/ZDV)",
            "21-day Lamivudine/Zidovudine (3TC/ZDV)",
            "7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)",
            "21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)",
            "7-day Lopinavir/Ritonavir (LPV/r)",
            "21-day Lopinavir/Ritonavir (LPV/r)"
        ],
        [
            "Description",
            "SD NVP and 3TC/ZDV provided at onset of active labor, followed by 7 days of 3TC/ZDV.",
            "SD NVP and 3TC/ZDV provided at onset of active labor, followed by 21 days of 3TC/ZDV.",
            "SD NVP and FTC/TDF provided at onset of active labor, followed by 7 days of FTC/TDF.",
            "SD NVP and FTC/TDF provided at onset of active labor, followed by 21 days of FTC/TDF.",
            "SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r.",
            "SD NVP and LPV/r provided at onset of active labor, followed by 7 days of LPV/r"
        ]
    ],
    "pageTitle": "Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00099632?sect=X01256&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438043062635.98/warc/CC-MAIN-20150728002422-00037-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 856213399,
    "recordOffset": 856191123,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups 62 participants who randomized but did not start study treatment were excluded from the analysis. These 62 participants were either off study prior to delivery or delivered on study but did not take any dose of study treatment. All the analyses were restricted to the 422 women who received study treatment. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Study participants were recruited at 8 sites: 2 from South Africa, 2 from India, and 1 each from Haiti, Uganda, Tanzania, and Malawi, between January 2007 to October 2009. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Emtricitabine/Tenofovir Disoproxil Fumarate Drug: Lamivudine/Zidovudine Drug: Lopinavir/Ritonavir Drug: single dose Nevirapine",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 7-day Lamivudine/Zidovudine (3TC/ZDV) \u00a0 \u00a0 21-day Lamivudine/Zidovudine (3TC/ZDV) \u00a0 \u00a0 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) \u00a0 \u00a0 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) \u00a0 \u00a0 7-day Lopinavir/Ritonavir (LPV/r) \u00a0 \u00a0 21-day Lopinavir/Ritonavir (LPV/r) \u00a0 STARTED \u00a0 \u00a0 73 \u00a0 \u00a0 68 \u00a0 \u00a0 75 \u00a0 \u00a0 67 \u00a0 \u00a0 71 \u00a0 \u00a0 68 \u00a0 COMPLETED \u00a0 \u00a0 72 \u00a0 \u00a0 67 \u00a0 \u00a0 72 \u00a0 \u00a0 66 \u00a0 \u00a0 70 \u00a0 \u00a0 66 \u00a0 NOT COMPLETED \u00a0 \u00a0 1 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}